OUR STORYFIGHTING CANCER, one cell at a time
X-ZELL is a global biotechnology company aiming to fundamentally reshuffle the way we diagnose and manage one of the most pressing health issues of our time – cancer.
Ranked among Asia’s 20 most innovative health technology start-ups, X-ZELL has developed a new platform technology capable of detecting tumour-derived Circulating Endothelial Cells (tCEC) in a small, 10mL blood sample.
Long considered ‘undetectable’ in clinical routine, these ultra-rare cells help physicians diagnose clinically significant cancer early, when it can be cured – in turn avoiding more than 70% of unnecessary interventions and saving billions to health systems worldwide.
Since stepping onto the global stage at Y Combinator’s March 2016 Demo Day, X-ZELL has managed to bring this – still unprecedented – knowledge from mind to market and develop the world’s first tCEC-based liquid biopsy, X-ZELL Prostate™. It’s the first in a series of blood tests that will be able to detect clinically significant disease early, pain-free and with unparalleled accuracy.
At the same time, X-ZELL has managed to bring the underlying platform technology from prototype stage to series production, with a global product launch slated for 26-28 March 2019 at the MEDLAB Asia Pacific show in Singapore.
Backed by leading investors from Thailand, Singapore and the US, X-ZELL is rapidly scaling up for global growth, with an internationally experienced management team in place and Singapore’s iconic DxD Hub at the ready to supercharge productisation.
ZERO DEATHS DUE TO UNDECTED CANCER
To us at X-ZELL, health is the true foundation of human achievement, so we believe that making it universally accessible will ultimate contribute to unleashing humanity’s true potential and help us lead our best, most fulfilled lives.
To make health accessible at scale, we decided against fighting existing disease and instead focused on detecting it early, before it can cause any harm – starting off with the most pressing health issue of our time, cancer.
The result is a simple, yet ambitious vision – to reduce the number of deaths caused by undetected disease to zero.
We call it Vision Zero.
Sebastian Chakrit Punyaratabandhu Bhakdi
The mastermind behind X-ZELL’s rare-cell detection technologies and a firm advocate of health equality, Dr Sebastian Chakrit Punyaratabandhu Bhakdi studied at one of the world’s oldest and most renowned medical schools, the University of Freiburg (Germany). As a medical student, he took internships in Bangkok (Thailand), Lahti (Finland), Skopje (Macedonia), Nairobi (Kenya) and New York (USA), which drew his attention to health service accessibility and inequality early on.
After graduating with dissertation magna cum laude, the classically trained musician went on to work in paediatrics and emergency medicine before earning a Postgraduate Master’s Degree in International Health and Tropical Medicine at the Autonomous University of Barcelona. While still in Barcelona, he won a Malaria Research Fellowship from the German Research Foundation and was subsequently invited to join the Department of Pathobiology at Mahidol University in Bangkok, Thailand.
Soon after, Thailand set the backdrop for the creation of X-ZELL, which has allowed the father of three to follow his entrepreneurial aspirations while proactively pursuing his passion for technological innovation to provide access to quality health care worldwide.
Head of Software Development & Design
Bart Van der Voort
Head of Engineering & Quality
Head of Marketing & Communications